Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Alkermes makes and sells medicines that treat alcohol and opioid addiction and serious mental illnesses like schizophrenia and bipolar disorder.
Alkermes is a drugmaker with a split personality, and that split is the key to understanding it. On one side, it sells its own branded medicines that treat addiction and serious mental illness. On the other, it runs a quieter business making the advanced delivery technology inside other companies' drugs, so a pill or injection works better than it otherwise would.
The branded side is where the story lives. Its biggest product is Vivitrol, a once-a-month injection for people fighting alcohol or opioid dependence — a shot instead of a daily pill, which matters for patients who struggle to stay on a routine. It also sells medicines for schizophrenia and bipolar I disorder, including Aristada, a long-acting injectable antipsychotic. These are treatments for people with hard, chronic conditions, and the company sells them mainly to doctors, clinics, and the healthcare system that pays for them. The other half is the manufacturing and technology arm. Alkermes has spent years perfecting ways to package drugs so they release slowly, dissolve better, or last for weeks instead of hours. Big drugmakers pay it to use that know-how on their own products, which brings in royalties and manufacturing fees without Alkermes having to market anything itself. It is steady, unglamorous money that helps fund the riskier branded business.
Alkermes is based in Ireland but runs much of its operation out of Massachusetts, and it is not a giant — it competes in corners of medicine that huge drugmakers often ignore. The company has been reshaping itself in recent years, separating parts of its business and sharpening its focus on addiction and neuroscience. The honest tension is this: addiction and mental illness are enormous problems with real need, but selling treatments for them is hard, because stigma, insurance rules, and patient habits all get in the way. Alkermes' bet is that better delivery — a shot that lasts a month instead of a pill every morning — can quietly beat those obstacles.
Saved answer · last researched 15 Nov 2026